A phase II study of methylphenidate for depression in advanced cancer

Jade Homsi, Kristine A. Nelson, Nabeel Sarhill, Lisa Rybicki, Susan B. Legrand, Mellar P. Davis, Declan Walsh

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

This study evaluated the use of methylphenidate for depression in advanced cancer. Design: Phase II open-label prospective study. Eligibility criteria: No previous use of methylphenidate or current use of other antidepressants. Evaluation: Depression and response to treatment were determined by asking the patient: “are you depressed?” Patients were assessed at baseline and at days 3, 5, and 7. Treatment: Starting dose was 5 mg at 8:00 a.m. and 12:00 noon. The dose was titrated for lack of response on any of the assessment days. Response criteria: A negative response to the question: “are you depressed?” Results: Some 41 patients were enrolled and 30 (15 men, 15 women) completed the study. Median age was 68 years (range: 30-90). Methylphenidate was stopped for six patients because of side effects and five were not evaluable; 21 responded to 10 mg/day on day 3; the other nine responded to 20 mg/day on day 5; 29 maintained their positive response through day 7. Anorexia, fatigue, concentration, and sedation also improved in some. All who completed the study had tolerable side effects, none of which caused treatment to stop. Conclusions: Methylphenidate is effective for depression in advanced cancer. A starting dose of 10 mg in divided doses is effective in most patients. Dose escalation may be needed. Improvement occurs within three days. Close monitoring of side effects is recommended.

Original languageEnglish (US)
Pages (from-to)403-407
Number of pages5
JournalAmerican Journal of Hospice and Palliative Medicine
Volume18
Issue number6
DOIs
StatePublished - Jan 1 2001

Fingerprint

Methylphenidate
Neoplasms
Anorexia
Antidepressive Agents
Fatigue
Therapeutics
Prospective Studies

Keywords

  • antidepressants
  • cancer
  • depression
  • existential issues
  • methylphenidate
  • psychiatric symptoms
  • psychological symptoms
  • symptom management

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A phase II study of methylphenidate for depression in advanced cancer. / Homsi, Jade; Nelson, Kristine A.; Sarhill, Nabeel; Rybicki, Lisa; Legrand, Susan B.; Davis, Mellar P.; Walsh, Declan.

In: American Journal of Hospice and Palliative Medicine, Vol. 18, No. 6, 01.01.2001, p. 403-407.

Research output: Contribution to journalArticle

Homsi, Jade ; Nelson, Kristine A. ; Sarhill, Nabeel ; Rybicki, Lisa ; Legrand, Susan B. ; Davis, Mellar P. ; Walsh, Declan. / A phase II study of methylphenidate for depression in advanced cancer. In: American Journal of Hospice and Palliative Medicine. 2001 ; Vol. 18, No. 6. pp. 403-407.
@article{07704e1526c44e63b0942a7d581ae75d,
title = "A phase II study of methylphenidate for depression in advanced cancer",
abstract = "This study evaluated the use of methylphenidate for depression in advanced cancer. Design: Phase II open-label prospective study. Eligibility criteria: No previous use of methylphenidate or current use of other antidepressants. Evaluation: Depression and response to treatment were determined by asking the patient: “are you depressed?” Patients were assessed at baseline and at days 3, 5, and 7. Treatment: Starting dose was 5 mg at 8:00 a.m. and 12:00 noon. The dose was titrated for lack of response on any of the assessment days. Response criteria: A negative response to the question: “are you depressed?” Results: Some 41 patients were enrolled and 30 (15 men, 15 women) completed the study. Median age was 68 years (range: 30-90). Methylphenidate was stopped for six patients because of side effects and five were not evaluable; 21 responded to 10 mg/day on day 3; the other nine responded to 20 mg/day on day 5; 29 maintained their positive response through day 7. Anorexia, fatigue, concentration, and sedation also improved in some. All who completed the study had tolerable side effects, none of which caused treatment to stop. Conclusions: Methylphenidate is effective for depression in advanced cancer. A starting dose of 10 mg in divided doses is effective in most patients. Dose escalation may be needed. Improvement occurs within three days. Close monitoring of side effects is recommended.",
keywords = "antidepressants, cancer, depression, existential issues, methylphenidate, psychiatric symptoms, psychological symptoms, symptom management",
author = "Jade Homsi and Nelson, {Kristine A.} and Nabeel Sarhill and Lisa Rybicki and Legrand, {Susan B.} and Davis, {Mellar P.} and Declan Walsh",
year = "2001",
month = "1",
day = "1",
doi = "10.1177/104990910101800610",
language = "English (US)",
volume = "18",
pages = "403--407",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - A phase II study of methylphenidate for depression in advanced cancer

AU - Homsi, Jade

AU - Nelson, Kristine A.

AU - Sarhill, Nabeel

AU - Rybicki, Lisa

AU - Legrand, Susan B.

AU - Davis, Mellar P.

AU - Walsh, Declan

PY - 2001/1/1

Y1 - 2001/1/1

N2 - This study evaluated the use of methylphenidate for depression in advanced cancer. Design: Phase II open-label prospective study. Eligibility criteria: No previous use of methylphenidate or current use of other antidepressants. Evaluation: Depression and response to treatment were determined by asking the patient: “are you depressed?” Patients were assessed at baseline and at days 3, 5, and 7. Treatment: Starting dose was 5 mg at 8:00 a.m. and 12:00 noon. The dose was titrated for lack of response on any of the assessment days. Response criteria: A negative response to the question: “are you depressed?” Results: Some 41 patients were enrolled and 30 (15 men, 15 women) completed the study. Median age was 68 years (range: 30-90). Methylphenidate was stopped for six patients because of side effects and five were not evaluable; 21 responded to 10 mg/day on day 3; the other nine responded to 20 mg/day on day 5; 29 maintained their positive response through day 7. Anorexia, fatigue, concentration, and sedation also improved in some. All who completed the study had tolerable side effects, none of which caused treatment to stop. Conclusions: Methylphenidate is effective for depression in advanced cancer. A starting dose of 10 mg in divided doses is effective in most patients. Dose escalation may be needed. Improvement occurs within three days. Close monitoring of side effects is recommended.

AB - This study evaluated the use of methylphenidate for depression in advanced cancer. Design: Phase II open-label prospective study. Eligibility criteria: No previous use of methylphenidate or current use of other antidepressants. Evaluation: Depression and response to treatment were determined by asking the patient: “are you depressed?” Patients were assessed at baseline and at days 3, 5, and 7. Treatment: Starting dose was 5 mg at 8:00 a.m. and 12:00 noon. The dose was titrated for lack of response on any of the assessment days. Response criteria: A negative response to the question: “are you depressed?” Results: Some 41 patients were enrolled and 30 (15 men, 15 women) completed the study. Median age was 68 years (range: 30-90). Methylphenidate was stopped for six patients because of side effects and five were not evaluable; 21 responded to 10 mg/day on day 3; the other nine responded to 20 mg/day on day 5; 29 maintained their positive response through day 7. Anorexia, fatigue, concentration, and sedation also improved in some. All who completed the study had tolerable side effects, none of which caused treatment to stop. Conclusions: Methylphenidate is effective for depression in advanced cancer. A starting dose of 10 mg in divided doses is effective in most patients. Dose escalation may be needed. Improvement occurs within three days. Close monitoring of side effects is recommended.

KW - antidepressants

KW - cancer

KW - depression

KW - existential issues

KW - methylphenidate

KW - psychiatric symptoms

KW - psychological symptoms

KW - symptom management

UR - http://www.scopus.com/inward/record.url?scp=0035512124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035512124&partnerID=8YFLogxK

U2 - 10.1177/104990910101800610

DO - 10.1177/104990910101800610

M3 - Article

C2 - 11712722

AN - SCOPUS:0035512124

VL - 18

SP - 403

EP - 407

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 6

ER -